Pharmacological postconditioning with atorvastatin calcium attenuates myocardial ischemia/reperfusion injury in diabetic rats by phosphorylating GSK3β

Abstract

Diabetes is an independent risk factor for myocar­dial ischemia, and many epidemiological data and laboratory studies have revealed that diabetes significantly exacerbated myocardial ischemia/reperfusion injury and ameliorated protective effects. The present study aimed to determine whether pharmacological postconditioning with atorvastatin calcium lessened diabetic myocardial ischemia/reperfu­sion injury, and investigated the role of glycogen synthase kinase (GSK3β) in this. A total of 72 streptozotocin‑induced diabetic rats were randomly divided into six groups, and 24 age‑matched male non‑diabetic Sprague‑Dawley rats were randomly divided into two groups. Rats all received 40 min myocardial ischemia followed by 180 min reperfu­sion, except sham‑operated groups. Compared with the non‑diabetic ischemia/reperfusion model group, the diabetic ischemia/reperfusion group had a comparable myocardial infarct size, but a higher level of serum cardiac troponin I (cTnI) and morphological alterations to their myocardial cells. Compared with the diabetic ischemia/reperfusion group, the group that received pharmacological postconditioning with atorvastatin calcium had smaller myocardial infarct sizes, lower levels of cTnI, reduced morphological alterations to myocardial cells, higher levels of p‑GSK3β, heat shock factor (HSF)‑1 and heat shock protein (HSP)70. The cardioprotec­tive effect conferred by atorvastatin calcium did not attenuate myocardial ischemia/reperfusion injury following application of TDZD‑8, which phosphorylates and inactivates GSK3β. Pharmacological postconditioning with atorvastatin calcium may attenuate diabetic heart ischemia/reperfusion injury in the current context. The phosphorylation of GSK3β serves a critical role during the cardioprotection in diabetic rats, and p‑GSK3β may accelerate HSP70 production partially by acti­vating HSF‑1 during myocardial ischemic/reperfusion injury.